Asset Details
Do you wish to reserve the book?
Add-on to current guidelines for monitoring of SBS patients treated with teduglutide
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Add-on to current guidelines for monitoring of SBS patients treated with teduglutide
Do you wish to request the book?
Add-on to current guidelines for monitoring of SBS patients treated with teduglutide
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Add-on to current guidelines for monitoring of SBS patients treated with teduglutide
2026
Overview
By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.
